UBS AM
BNR

UBS AM’s Burning Rock Biotech BNR Stock Holding History

UBS AM’s Portfolio BNR Stock Details BNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-8,686
Closed -$1.55M – 2850
2021
Q3 		$1.55M Buy
8,686
+3,483
+67% +$774K ﹤0.01% 1946
2021
Q2 		$1.53M Buy
+5,203
New +$1.54M ﹤0.01% 1975

Other funds holding BNR

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
MICM
Matthews International Capital Management San Francisco, California $246M AUM 10.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

UBS AM's BNR Position: Q4 2021 in Review

UBS AM sold out of Burning Rock Biotech (BNR) in Q4 2021, closing a stake of 8,686 shares — an estimated $1.55M sold.

UBS AM first reported a position in BNR in Q2 2021 and held it in 2 quarters. The position peaked at $1.55M in Q3 2021. 62 funds tracked by Wall St. Rank hold BNR as of Q4 2021.

  • UBS AM reported no remaining Burning Rock Biotech position as of Q4 2021 after selling out during the quarter.
  • UBS AM sold 8,686 Burning Rock Biotech shares in Q4 2021, an estimated $1.55M.
  • UBS AM first reported a position in Burning Rock Biotech in Q2 2021 and held it in 2 quarters.
  • UBS AM's Burning Rock Biotech position peaked at $1.55M in Q3 2021.
  • 62 funds tracked by Wall St. Rank held Burning Rock Biotech as of Q4 2021.

Based on UBS AM's 13F filing for Q4 2021, filed 14 Feb 2022.